Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.
Feature|Articles|September 18, 2025
- Vol.26/No.12
- Volume 26
- Issue 12
Targeted Therapies Drive Demand for Comprehensive Biomarker Testing in NSCLC
Author(s)Ashling Wahner
Fact checked by: Chris Ryan, Tracy Ann Politowicz
Lung cancer experts share the evolution of biomarker testing that has led to advances in patient selection for treatment, as well as challenges that future developments may address.
Advertisement
Advertisement
The non–small cell lung cancer (NSCLC) treatment paradigm has welcomed the addition of numerous targeted therapies over the past several years, prompting a complementary increase in molecular testing rates and innovative tumor sequencing methods. However, persisting barriers to testing, such as tissue insufficiency, emphasize the need for increased diligence through repeat biopsies and improved testing alternatives such as liquid biopsies, according to lung cancer experts interviewed by OncLive®.
Related to this article
Mariana C. Stern, PhD, discusses the biggest gaps identified in the 2026 AACR Disparities Progress Report and what oncologists can do to combat them.
Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.
A growing clinical phenomenon of incidentally finding early-stage lung cancer suggests a significant gap in the current screening paradigm.
Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.
Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.
Prithviraj Bose, MD, overviews the ongoing investigation of sapablursen in polycythemia vera.
The DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan received FDA orphan drug designation for the management of neuroendocrine carcinomas.
Advertisement
Advertisement